WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Related articles:
Related suggestion:
Cologne left contemplating Bundesliga relegation after home loss to lastAP Photos: The skies fill with color at a Chinese kite festivalFelix Rosenqvist career turnaround continues as Swede gives Meyer Shank Racing 1st IndyCar poleTwins rightLongtime AP journalist, newspaper publisher John Brewer dies at age 76Remember me? Original Real Housewives of Orange County star Jo De La Rosa returns to the showPolice to review claims Tory MP Mark Menzies allegedly misused £14,000 of party fundsA rabbi serving 30 years to life in his wife's contract killing has died, prison officials sayConjoined twin's husband learns paternity test results after exBiden to announce U.S. military to build temporary port in Gaza for humanitarian aid
2.8176s , 6491.171875 kb
Copyright © 2024 Powered by Why Amylyx is pulling ALS drug Relyvrio from US market after study ,Culture Craft news portal